Latest News

Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares




BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common and Series B Preferred Shares announced February 22, 2019. On February 22, 2019, as announced by press release, the Sinovac Board of Directors effectuated an Exchange of Rights held by certain Sinovac’s shareholders for a combination of approximately 27.8 million Common Shares and approxim

Source link




Related posts

How Are You Feeling? Check Your Wristband

Newsemia

DNA technology as a novel strategy for delivery of anti-HIV antibodies

Newsemia

Gene-editing Chinese scientist kept much of his work secret

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy